



MEDICAL TIPS

TENEBLU Tablets

Issue II, No. 5, 2023

Systemic review and meta-analysis of teneligliptin for treatment of type 2 diabetes.

Pelluri R et al. Journal of Endocrinological Investigation 2023.

- A systemic review of RCTs was undertaken to comprehensively profile the safety and efficacy of teneligliptin in the treatment of type 2 diabetes.
- 13 studies enrolling 2853 patients were chosen for the RCTs using teneligliptin as monotherapy or as an adjunct to other glycaemic agents.
- Compared to monotherapy, teneligliptin used as an add on therapy showed a significant improvement in the FPG whereas, the improvement in the HbA1c was greater with monotherapy.
- There was no significant risk of hypoglycaemia with teneligliptin as compared to placebo.

Teneligliptin is an effective and safe therapeutic option for patients with type 2 diabetes both as monotherapy and as add-on therapy.

